Urea Cycle Disorders Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2022-2032), States DelveInsight | Key Companies – Bausch Health Companies Inc.

DelveInsight’s “Urea Cycle Disorders Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Urea Cycle Disorders, historical and forecasted epidemiology as well as the Urea Cycle Disorders market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Urea Cycle Disorders market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

To

Know in detail about the Urea Cycle Disorders market outlook, drug uptake, treatment scenario andepidemiology trends, Click here; Urea Cycle Disorders Market Insights

Urea Cycle Disorders Overview

Urea cycle disorders (UCDs) are congenital error of nitrogen detoxification/arginine synthesis due to defects in the urea cycle enzymes such as carbamoylphosphate synthetase 1 (CPS1), ornithine transcarbamylase (OTC), argininosuccinate synthetase (ASS), argininosuccinate lyase (ASL) and arginase 1 (ARG1), leading to respective deficiencies (abbreviated CPS1D, OTCD, ASSD, ASLD and ARG1D).

Some of the key facts of the Urea Cycle Disorders Market Report: 

• The Urea Cycle Disorders market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• According to Van Leung-Pineda (2019), the prevalence of Urea Cycle Disorders in US is approximated to be 1 in 35,000, with two-thirds having symptoms in the neonatal period
• According to Kido et al. (2021), the estimated prevalence of Urea Cycle Disorders is 1 per 50,000 live births in Japan
• According to Batshaw et al. (2014), the mortality rate of Urea Cycle Disorders is 24% in neonatal onset cases and 11% in late onset cases
• Key Urea Cycle Disorders Companies: Bausch Health Companies Inc., Recordati Rare Diseases, Eurocept Pharmaceuticals Holding (Lucane Pharma SA), Arcturus Therapeutics, Inc., Orpharma Pty Ltd., Selecta Biosciences, Inc, and Abbott Laboratories, Acer Therapeutics, Aeglea BioTherapeutics, Ultragenyx Pharmaceutical, and others
• Key Urea Cycle Disorders Therapies: ACER-001, AEB1102, DTX301, and others
• The Urea Cycle Disorders epidemiology based on gender analyzed that OTC deficiency affects males more often than females and most males are symptomatic in nature. In males, symptoms typically begin during the first few days of life

Get a Free sample for the Urea Cycle Disorders Market Report –

https://www.delveinsight.com/sample-request/urea-cycle-disorders-market

Key benefits of the Urea Cycle Disorders Market report:

1. Urea Cycle Disorders market report covers a descriptive overview and comprehensive insight of the Urea Cycle Disorders Epidemiology and Urea Cycle Disorders market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. The Urea Cycle Disorders market report provides insights on the current and emerging therapies.
3. Urea Cycle Disorders market report provides a global historical and forecasted market covering drug outreach in 7MM.
4. The Urea Cycle Disorders market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Urea Cycle Disorders market.

Download the report to understand which factors are driving Urea Cycle Disorders epidemiology trends @ Urea Cycle Disorders Epidemiological Insights 

Urea Cycle Disorders Market

The dynamics of the Urea Cycle Disorders market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032. 

“The physicians’ most frequent responses regarding unmet needs in Urea Cycle Disorders care included were under-recognition of asymptomatic hyperammonemia (72%), poor adherence to Urea Cycle Disorders treatment (67%), and side effects, poor tolerability, and/or administering Urea Cycle Disorders medications (64%) (n = 64).”

Urea Cycle Disorders Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Urea Cycle Disorders Epidemiology Segmentation:

The Urea Cycle Disorders market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Urea Cycle Disorders
• Prevalent Cases of Urea Cycle Disorders by severity
• Gender-specific Prevalence of Urea Cycle Disorders
• Diagnosed Cases of Episodic and Chronic Urea Cycle Disorders

Urea Cycle Disorders Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Urea Cycle Disorders market or expected to get launched during the study period. The analysis covers Urea Cycle Disorders market uptake by drugs, patient uptake by therapies, and sales of each drug.  

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Urea Cycle Disorders Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Discover more about therapies set to grab major Urea Cycle Disorders market share @ Urea Cycle Disorders market forecast 

Urea Cycle Disorders Therapies and Key Companies

• ACER-001: Acer Therapeutics
• AEB1102: Aeglea BioTherapeutics
• DTX301: Ultragenyx Pharmaceutical

Scope of the Urea Cycle Disorders Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Urea Cycle Disorders Companies: Bausch Health Companies Inc., Recordati Rare Diseases, Eurocept Pharmaceuticals Holding (Lucane Pharma SA), Arcturus Therapeutics, Inc., Orpharma Pty Ltd., Selecta Biosciences, Inc, and Abbott Laboratories, Acer Therapeutics, Aeglea BioTherapeutics, Ultragenyx Pharmaceutical, and others
• Key Urea Cycle Disorders Therapies: ACER-001, AEB1102, DTX301, and others
• Urea Cycle Disorders Therapeutic Assessment: Urea Cycle Disorders current marketed and Urea Cycle Disorders emerging therapies
• Urea Cycle Disorders Market Dynamics: Urea Cycle Disorders market drivers and Urea Cycle Disorders market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Urea Cycle Disorders Unmet Needs, KOL’s views, Analyst’s views, Urea Cycle Disorders Market Access and Reimbursement 

Table of Contents 

1. Urea Cycle Disorders Market Report Introduction

2. Executive Summary for Urea Cycle Disorders

3. SWOT analysis of Urea Cycle Disorders

4. Urea Cycle Disorders Patient Share (%) Overview at a Glance

5. Urea Cycle Disorders Market Overview at a Glance

6. Urea Cycle Disorders Disease Background and Overview

7. Urea Cycle Disorders Epidemiology and Patient Population

8. Country-Specific Patient Population of Urea Cycle Disorders 

9. Urea Cycle Disorders Current Treatment and Medical Practices

10. Urea Cycle Disorders Unmet Needs

11. Urea Cycle Disorders Emerging Therapies

12. Urea Cycle Disorders Market Outlook

13. Country-Wise Urea Cycle Disorders Market Analysis (2019–2032)

14. Urea Cycle Disorders Market Access and Reimbursement of Therapies

15. Urea Cycle Disorders Market Drivers

16. Urea Cycle Disorders Market Barriers

17.  Urea Cycle Disorders Appendix

18. Urea Cycle Disorders Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

To know more about Urea Cycle Disorders treatment, visit @ Urea Cycle Disorders Medications

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services